MiNK Therapeutics (INKT) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free INKT Stock Alerts $0.89 +0.02 (+2.30%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Down 11.6% in Marchamericanbankingnews.com - April 16 at 5:34 AMThis MiNK Therapeutics Insider Increased Their Holding In The Last Yearfinance.yahoo.com - April 11 at 8:52 AMMiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACRglobenewswire.com - April 8 at 12:00 PMBuy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial Movesmarkets.businessinsider.com - March 25 at 2:42 AMMiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 22 at 3:06 PMPromising Clinical Progress and Market Potential for MiNK Therapeutics’ agenT-797 in Gastric Cancer Studymarkets.businessinsider.com - March 21 at 4:07 PMINKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023investorplace.com - March 21 at 12:09 PMMiNK Reports Fourth Quarter and Year-End 2023 Resultsglobenewswire.com - March 21 at 7:00 AMEarnings Outlook For MiNK Therapeuticsbenzinga.com - March 20 at 7:30 PMMiNK Therapeutics: MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024finanznachrichten.de - March 8 at 9:07 PMMiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Reportglobenewswire.com - March 7 at 7:30 AMMiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024globenewswire.com - March 6 at 8:30 AMCell therapy could help patients with ARDS from severe Covid-19, study involving ARU showsmsn.com - February 24 at 10:43 AMFirst Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimabfinance.yahoo.com - February 14 at 12:13 PMMiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communicationsfinance.yahoo.com - February 6 at 9:15 AMMiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogenefinance.yahoo.com - January 30 at 10:10 AMImmunoScape, MiNK Therapeutics Join To Develop Next-generation TCR Therapiesmarkets.businessinsider.com - December 20 at 12:57 PMImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Developmentfinance.yahoo.com - December 20 at 12:57 PMMiNK Therapeutics Inc INKTmorningstar.com - November 22 at 8:55 AMMiNK Therapeutics GAAP EPS of -$0.15msn.com - November 9 at 3:10 PMMiNK Therapeutics Reports Third Quarter 2023 Resultsfinance.yahoo.com - November 9 at 10:10 AMMiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challengesfinance.yahoo.com - November 9 at 10:10 AMMiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023finance.yahoo.com - November 3 at 1:42 PMMiNK Therapeutics Insider Ups Holding During Yearfinance.yahoo.com - November 3 at 8:42 AMMiNK to Provide Third Quarter 2023 Financial Report and Corporate Updatefinance.yahoo.com - October 30 at 12:00 PMMiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023finance.yahoo.com - September 27 at 1:21 PMCan MiNK Therapeutics (NASDAQ:INKT) Afford To Invest In Growth?finance.yahoo.com - September 23 at 1:21 PMMiNK Therapeutics to Participate in September Investor Conferencesfinance.yahoo.com - August 24 at 12:58 PMMiNK Therapeutics: In The Very Early Days Of A Big Huntmsn.com - August 23 at 6:37 AMMink Therapeutics winst hoger dan voorspeld, omzet volgens verwachtingnl.investing.com - August 10 at 5:00 PMMiNK Therapeutics Reports Second Quarter 2023 Resultsfinance.yahoo.com - August 10 at 11:18 AMMiNK to Provide Second Quarter 2023 Financial Report and Corporate Updatefinance.yahoo.com - July 28 at 9:27 AM"Off-the-shelf" cell therapy shows promise for cancers resistant to current treatments, including immunotherapiescbsnews.com - May 23 at 4:31 PMMiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conferencefinance.yahoo.com - May 22 at 12:46 PMB.Riley Financial Sticks to Their Buy Rating for MiNK Therapeutics (INKT)markets.businessinsider.com - May 18 at 11:31 PMMiNK's Novel FAP-CAR-iNKT Presented at ASGCTfinance.yahoo.com - May 18 at 1:29 PMRobert W. Baird Reaffirms Their Buy Rating on MiNK Therapeutics (INKT)markets.businessinsider.com - May 15 at 8:09 AMRecap: MiNK Therapeutics Q1 Earningsmsn.com - May 12 at 12:43 PMThe Latest Analyst Ratings for MiNK Therapeuticsmsn.com - May 12 at 12:43 PMMiNK Therapeutics (INKT) Has a New Rating from H.C. Wainwrightmarkets.businessinsider.com - May 12 at 7:43 AMB.Riley Financial Keeps Their Buy Rating on MiNK Therapeutics (INKT)markets.businessinsider.com - May 12 at 7:43 AMMiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Resultsfinance.yahoo.com - May 11 at 9:48 AMMiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Resultsfinance.yahoo.com - April 27 at 9:11 AMRobert W. Baird Keeps Their Buy Rating on MiNK Therapeutics (INKT)markets.businessinsider.com - April 21 at 2:40 PMMiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meetingfinance.yahoo.com - April 18 at 5:15 PMWe're Keeping An Eye On MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Ratefinance.yahoo.com - April 16 at 8:45 AMMiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - April 4 at 1:58 PMAgenus Announces Dividend of 5 Million Shares of MiNK Therapeuticsfinance.yahoo.com - March 30 at 9:26 AMMiNK Therapeutics, Inc. (INKT) Upgraded to Buy: What Does It Mean for the Stock?finance.yahoo.com - March 29 at 3:13 PMMiNK Therapeutics: iNKT Therapy Data Should Drive Stock Price Upseekingalpha.com - March 25 at 7:52 AM Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… INKT Media Mentions By Week INKT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INKT News Sentiment▼0.000.43▲Average Medical News Sentiment INKT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INKT Articles This Week▼00▲INKT Articles Average Week Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Achilles Therapeutics News Today IN8bio News Today Protara Therapeutics News Today Pluri News Today Cyclo Therapeutics News Today Tevogen Bio News Today NKGen Biotech News Today AIM ImmunoTech News Today OKYO Pharma News Today Evaxion Biotech A/S News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INKT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
